On Heels Of Emerging Markets Deal, Merck Ropes In India's Sun Pharma To Boost Januvia Sales
This article was originally published in PharmAsia News
MUMBAI - In an attempt to add more teeth to its rapidly growing anti-diabetes franchise in India, Merck & Co.'s affiliate MSD India and Sun Pharmaceutical Industries Ltd. jointly announced the formation of an "India-specific strategic partnership" under which Sun will have the right to market, promote and distribute MSD's star products Januvia (sitagliptin) and Janumet (sitagliptlin/metformin) under different brand names
You may also be interested in...
Merck’s Indian arm MSD India has linked up with a financial institution and is considering national rollout of a funding plan that aims to stretch the cost of hepatitis C treatment over several months. The impact could mean that up to about 45% of the affected population might get treatment, up from 3% now.
In what could perhaps be the first such experiment in the Indian pharmaceutical industry, Merck’s Indian arm MSD India has linked up with a financial institution and is considering a national rollout of a funding plan that aims to expand the cost of hepatitis C treatment over several months, thereby easing the burden on needy patients. The bigger gain could mean that from just 3% of the population that get treated for the fatal disease the number could swell to roughly 45% of the population.
In the latest overhaul of its commercial operations, Merck shared enthusiasm about prospects in emerging markets. But it did not include India, Turkey and Poland in its list of top 10 priority markets, a change from its vision shared just four years ago